MG-132 [133407-82-6]
Cat# HY-13259-50mg
Size : 50mg
Brand : MedChemExpress
Please arrange your schedule properly.
- United States
- Canada
- United Kingdom
- Australia
- Germany
- France
- Japan
- Korea South
- Switzerland
- Algeria
- Argentina
- Austria
- Belgium
- Brazil
- Chile
- Croatia
- Czech Republic
- Denmark
- Finland
- Hong Kong, China
- Hungary
- India
- Iraq
- Ireland
- Israel
- Italy
- Lebanon
- Luxembourg
- Malaysia
- Mexico
- Morocco
- Netherlands
- New Zealand
- Norway
- Pakistan
- Peru
- Philippines
- Poland
- Portugal
- Qatar
- Russia
- Saudi Arabia
- Serbia
- Singapore
- Slovakia
- Slovenia
- South Africa
- Spain
- Sweden
- Taiwan, China
- Thailand
- Tunisia
- Turkey
- Ukraine
- Macao, China
- Other Countries
MG-132 (Synonyms: Z-Leu-Leu-Leu-al; MG132)
- Cat. No.: HY-13259 Purity: 99.97%
- COA Handling Instructions
MG-132 est un inhibiteur puissant et réversible du protéasome avec un IC50 de 100 nM. MG-132 bloque efficacement l'activité protéolytique du complexe de protéasome 26S. MG-132, un peptide aldéhyde, est un activateur d'autophagie.
MG-132 (Z-Leu-leu-leu-al) ist ein potenter proteasome- und calpain-Inhibitor mit IC50s von 100 nM bzw. 1,2 μM. MG-132 blockiert wirksam die proteolytische Aktivität des 26S-Proteasomkomplexes. MG-132, ein Peptidaldehyd, ist ebenfalls ein autophagy-Aktivator.
MG-132 (Z-Leu-Leu-Leu-al) is a potent proteasome and calpain inhibitor with IC50s of 100 nM and 1.2 μM, respectively. MG-132 effectively blocks the proteolytic activity of the 26S proteasome complex. MG-132, a peptide aldehyde, also is an autophagy activator. MG-132 also induces apoptosis.
For research use only. We do not sell to patients.
MG-132 Chemical Structure
CAS No. : 133407-82-6
Size | Price | Stock | Quantity |
---|---|---|---|
Free Sample (0.1 - 0.5 mg) | Apply Now | ||
5 mg | USD 50 | In-stock | |
10 mg | USD 80 | In-stock | |
25 mg | USD 180 | In-stock | |
50 mg | USD 290 | In-stock | |
100 mg | USD 450 | In-stock | |
200 mg | USD 620 | In-stock | |
500 mg | USD 980 | In-stock | |
1 g | Get quote | ||
5 g | Get quote |
* Please select Quantity before adding items.
This product is a controlled substance and not for sale in your territory.
Customer Review
Based on 903 publication(s) in Google Scholar
Other Forms of MG-132:
- (R)-MG-132 In-stock
- MG-132 (negative control) In-stock
- •Mol Cancer. 2024 Jan 24;23(1):23. [Abstract]
- •Cell Discov. 2023 Jul 25;9(1):76. [Abstract]
- •Cell Res. 2023 Jul 17. [Abstract]
- •Cancer Cell. 2023 Jun 12;41(6):1073-1090.e12. [Abstract]
- •Mol Cancer. 2023 May 20;22(1):86. [Abstract]
- •Cell Discov. 2023 Mar 7;9(1):26. [Abstract]
- •Cell. 2023 Feb 16;186(4):803-820.e25. [Abstract]
- •Signal Transduct Target Ther. 2023 Jan 16;8(1):18. [Abstract]
- •Cancer Cell. 2022 Sep 19;S1535-6108(22)00436-6. [Abstract]
- •Nat Immunol. 2022 Aug;23(8):1193-1207. [Abstract]
- •Signal Transduct Target Ther. 2022 Jan 24;7(1):21. [Abstract]
- •Nature. 2021 Nov;599(7885):491-496. [Abstract]
- •Cell Res. 2021 Sep 3. [Abstract]
- •Signal Transduct Target Ther. 2020 Dec 26;5(1):298. [Abstract]
- •Cell Res. 2021 Mar;31(3):291-311. [Abstract]
- •Science. 2020 Dec 4;370(6521):eaay2002. [Abstract]
- •Cell Metab. 2023 Dec 15:S1550-4131(23)00450-3. [Abstract]
- •Cell Metab. 2023 Jun 14;S1550-4131(23)00209-7. [Abstract]
- •Cell Metab. 2021 May 4;33(5):971-987.e6. [Abstract]
- •J Hematol Oncol. 2021 Jan 7;14(1):9. [Abstract]
- •Nat Neurosci. 2023 Mar 27. [Abstract]
- •Drug Resist Updat. 2023 Jan 25.
- •Protein Cell. 21 September 2022.
- •Nat Metab. 2022 Sep;4(9):1202-1213. [Abstract]
- •Nat Cell Biol. 2022 Apr;24(4):497-512. [Abstract]
- •Natl Sci Rev. 2021 Feb 10;8(7):nwab024. [Abstract]
- •Cell Mol Immunol. 2022 Jan;19(1):67-78. [Abstract]
- •Nat Cell Biol. 2021 Mar;23(3):257-267. [Abstract]
- •Blood. 2021 Mar 18;137(11):1478-1490. [Abstract]
- •Protein Cell. 2021 Feb;12(2):107-127. [Abstract]
- •Cell Mol Immunol. 2020 May;17(5):496-506. [Abstract]
- •Nat Commun. 2024 Mar 16. [Abstract]
- •Nat Commun. 2019 Sep 19;10(1):4266. [Abstract]
- •Mol Cell. 2024 Feb 9:S1097-2765(24)00091-1. [Abstract]
- •Mol Cell. 2020 Jan 2;77(1):95-107.e5. [Abstract]
- •Adv Sci (Weinh). 2024 Jan 6:e2305260. [Abstract]
- •Adv Sci (Weinh). 2023 Dec 12:e2305620. [Abstract]
- •Adv Sci (Weinh). 2023 Dec 7:e2305374. [Abstract]
- •ACS Nano. 2023 Nov 15. [Abstract]
- •Mol Cell. 2023 Nov 20:S1097-2765(23)00914-0. [Abstract]
- •Adv Sci (Weinh). 2023 Nov 16:e2306535. [Abstract]
- •Nat Commun. 2023 Oct 10;14(1):6332. [Abstract]
- •Chem Eng J. 2023 Nov 1, 475, 146449.
- •Adv Sci (Weinh). 2023 Oct 27:e2300698. [Abstract]
- •Adv Sci (Weinh). 2023 Oct 22:e2302953. [Abstract]
- •Nat Commun. 2023 Sep 21;14(1):5891. [Abstract]
- •Adv Sci (Weinh). 2023 Oct;10(28):e2302130. [Abstract]
- •Nat Commun. 2023 Jul 14;14(1):4217. [Abstract]
- •Adv Sci (Weinh). 2023 Jul 3;e2207549. [Abstract]
- •Nat Struct Mol Biol. 2023 May 15. [Abstract]
- •Nat Commun. 2023 May 19;14(1):2859. [Abstract]
- •Nat Commun. 2023 May 5;14(1):2602. [Abstract]
- •Cancer Commun (Lond). 2023 Apr 2. [Abstract]
- •Neuro Oncol. 2023 Apr 21;noad079. [Abstract]
- •Nat Commun. 2023 Mar 18;14(1):1521. [Abstract]
- •Adv Sci (Weinh). 2023 Feb 12;e2206792. [Abstract]
- •Nat Plants. 2023 Jan 16. [Abstract]
- •Nat Commun. 2023 Jan 4;14(1):61. [Abstract]
- •Adv Sci (Weinh). 2022 Dec 11;e2204018. [Abstract]
- •Nat Commun. 2022 Sep 23;13(1):5594. [Abstract]
- •Nat Commun. 2022 Sep 2;13(1):5173. [Abstract]
- •Mol Cell. 2022 Aug 10;S1097-2765(22)00663-3. [Abstract]
- •Nat Commun. 2022 Jun 28;13(1):3706. [Abstract]
- •Neuro Oncol. 2022 Jun 21;noac157. [Abstract]
- •Nat Commun. 2022 May 31;13(1):3034. [Abstract]
- •Mol Cell. 2022 May 19;82(10):1821-1835.e6. [Abstract]
- •Nat Commun. 2022 Apr 8;13(1):1923. [Abstract]
- •J Clin Invest. 2022 Mar 1;132(5):e152170. [Abstract]
- •ACS Cent Sci. February 2, 2022.
- •Mol Cell. 2021 Sep 10;S1097-2765(21)00696-1. [Abstract]
- •Nat Commun. 2021 Aug 24;12(1):5106. [Abstract]
- •Nat Commun. 2021 Jul 20;12(1):4413. [Abstract]
- •Nat Commun. 2021 Jun 3;12(1):3319. [Abstract]
- •Nat Plants. 2021 Feb;7(2):209-218. [Abstract]
- •Adv Sci (Weinh). 2020 Aug 5;7(19):2001041. [Abstract]
- •Mol Cell. 2020 Jul 16;79(2):304-319.e7. [Abstract]
- •Mol Cell. 2020 Jul 16;79(2):320-331.e9. [Abstract]
- •Mol Cell. 2020 Jan 2;77(1):95-107.e5. [Abstract]
- •Nat Commun. 2019 Sep 19;10(1):4266. [Abstract]
- •Brain Behav Immun. 2019 Jul;79:244-255. [Abstract]
- •Adv Sci (Weinh). 2019 Mar 25;6(10):1801862. [Abstract]
- •J Hazard Mater. 2024 Mar 27:470:134142. [Abstract]
- •Plant Cell. 2024 Mar 6:koae049. [Abstract]
- •Redox Biol. 2024 Mar 8, 103100.
- •J Exp Clin Cancer Res. 2024 Jan 2;43(1):7. [Abstract]
- •J Exp Clin Cancer Res. 2024 Feb 2;43(1):39. [Abstract]
- •Cell Rep Med. 2024 Jan 11:101357. [Abstract]
- •Cell Death Differ. 2024 Jan 16. [Abstract]
- •J Adv Res. 2024 Jan 12:S2090-1232(24)00025-0. [Abstract]
- •Nucleic Acids Res. 2023 Dec 6:gkad1176. [Abstract]
- •Acta Pharm Sin B. 2023 Dec 16.
- •J Hazard Mater. 2023 Dec 12, 133038.
- •Exp Hematol Oncol. 2023 Dec 16;12(1):105. [Abstract]
- •Autophagy. 2023 Nov 1:1-17. [Abstract]
- •EMBO J. 2023 Oct 31:e114558. [Abstract]
- •Cell Death Differ. 2023 Oct 12. [Abstract]
- •Theranostics. 2023 Sep 4;13(14):4919-4935. [Abstract]
- •Dev Cell. 2023 Oct 18:S1534-5807(23)00494-X. [Abstract]
- •Redox Biol. 2023 Oct 16, 102931.
- •J Exp Clin Cancer Res. 2023 Oct 7;42(1):261. [Abstract]
- •J Adv Res. 2023 Sep 28:S2090-1232(23)00291-6. [Abstract]
- •Nat Chem Biol. 2023 Aug 31. [Abstract]
- •Redox Biol. 2023 Sep 28:67:102896. [Abstract]
- •J Exp Clin Cancer Res. 2023 Aug 24;42(1):219. [Abstract]
- •J Hazard Mater. 2023 Jun 1, 131750.
- •Autophagy. 2023 Jun 13;1-17. [Abstract]
- •Cell Death Differ. 2023 Jun 15. [Abstract]
- •Cell Death Differ. 2023 Jun 19. [Abstract]
- •Clin Transl Med. 2023 Jun;13(6):e1300. [Abstract]
- •Redox Biol. 2023 Apr 17, 102705.
- •Proc Natl Acad Sci U S A. 2023 Apr 11;120(15):e2209435120. [Abstract]
- •EMBO J. 2023 Mar 27;e111980. [Abstract]
- •Redox Biol. 2023 Jun.
- •Hepatology. 2023 Jan 13. [Abstract]
- •Dev Cell. 2023 Feb 15;S1534-5807(23)00041-2. [Abstract]
- •J Adv Res. 2023 Feb 22;S2090-1232(23)00063-2. [Abstract]
- •Exp Mol Med. 2023 Jan;55(1):183-195. [Abstract]
- •EBioMedicine. 2023 Jan 27;88:104444. [Abstract]
- •Proc Natl Acad Sci U S A. 2023 Jan 31;120(5):e2213777120. [Abstract]
- •Autophagy. 2022 Nov 30. [Abstract]
- •Cell Death Differ. 2022 Dec 16. [Abstract]
- •J Exp Clin Cancer Res. 2022 Dec 29;41(1):364. [Abstract]
- •J Immunother Cancer. 2022;10:e005668.
- •Cell Death Differ. 2022 Nov 15. [Abstract]
- •J Med Virol. 2022 Oct 10. [Abstract]
- •Cell Death Differ. 2022 Oct 5. [Abstract]
- •Emerg Microbes Infect. 2022 Sep 14;1-48. [Abstract]
- •Exp Mol Med. 2022 Sep 21. [Abstract]
- •Nat Chem Biol. 2022 Aug 18. [Abstract]
- •Acta Pharm Sin B. 27 August 2022.
- •Sci Adv. 2022 Aug 26;8(34):eabq4722. [Abstract]
- •Autophagy. 2022 Jun 19;1-19. [Abstract]
- •Cell Death Differ. 2022 Aug 22. [Abstract]
- •Redox Biol. 20 August 2022, 102437.
- •Redox Biol. 2022 Oct;56:102435. [Abstract]
- •Clin Transl Med. 2022 Aug;12(8):e1003. [Abstract]
- •EBioMedicine. 2022 Jul 28;82:104181. [Abstract]
- •Cell Death Differ. 2022 Jun 22. [Abstract]
- •Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2202970119. [Abstract]
- •EMBO Mol Med. 2022 May 25;e15373. [Abstract]
- •Clin Transl Med. 2022 Apr;12(4):e797. [Abstract]
- •J Exp Clin Cancer Res. 2022 Mar 28;41(1):111. [Abstract]
- •Theranostics. 2022 Jan 24;12(4):1904-1920. [Abstract]
- •J Exp Clin Cancer Res. 2022 Jan 24;41(1):33. [Abstract]
- •Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2119995119. [Abstract]
- •Cell Death Differ. 2022 Jan 15. [Abstract]
- •Cell Death Differ. 2022 Mar;29(3):642-656. [Abstract]
- •Acta Pharm Sin B. 26 October 2021.
- •Clin Transl Med. 2021 Sep;11(9):e464. [Abstract]
- •J Hazard Mater. 15 February 2022, 127268.
- •Acta Pharm Sin B. 28 August 2021.
- •Theranostics. 2021 Jun 11;11(16):7640-7657. [Abstract]
- •Acta Pharm Sin B. 17 July 2021.
- •J Biomed Sci. 2021 Jul 23;28(1):55. [Abstract]
- •Clin Transl Med. 2021 Apr;11(4):e395. [Abstract]
- •J Exp Clin Cancer Res. 2021 May 7;40(1):158. [Abstract]
- •Theranostics. 2021 Mar 11;11(11):5279-5295. [Abstract]
- •Cell Death Differ. 2021 Aug;28(8):2367-2384. [Abstract]
- •Theranostics. 2021 Mar 4;11(10):4616-4636. [Abstract]
- •Acta Pharm Sin B. 2021 Feb 11.
- •Cell Death Differ. 2021 Jul;28(7):2221-2237. [Abstract]
- •Theranostics. 2021 Jan 1;11(2):841-860. [Abstract]
- •Sci Adv. 2021 Jan 1;7(1):eabe1340. [Abstract]
- •Theranostics. 2021 Jan 1;11(2):861-877. [Abstract]
- •Theranostics. 2021 Jan 1;11(3):1473-1492. [Abstract]
- •J Exp Clin Cancer Res. 2021 Apr 8;40(1):122. [Abstract]
- •Clin Transl Med. 2020 Dec;10(8):e240. [Abstract]
- •Redox Biol. 2020 Nov 1;38:101771. [Abstract]
- •Theranostics. 2020 May 16;10(14):6483-6499. [Abstract]
- •Theranostics. 2020 Aug 13;10(24):11110-11126. [Abstract]
- •Acta Pharm Sin B. 2021 Jan;11(1):71-88. [Abstract]
- •Cell Death Differ. 2021 Jan;28(1):337-348. [Abstract]
- •J Exp Clin Cancer Res. 2020 Sep 16;39(1):190. [Abstract]
- •J Med Virol. 2020 Aug 10. [Abstract]
- •Theranostics. 2020 Jul 9;10(19):8573-8590. [Abstract]
- •Autophagy. 2021 Jul;17(7):1684-1699. [Abstract]
- •Cell Death Differ. 2020 Nov;27(11):3177-3195. [Abstract]
- •Redox Biol. 2020 Jul;34:101559. [Abstract]
- •Cell Death Differ. 2020 Jul;27(7):2048-2065. [Abstract]
- •Cell Death Differ. 2020 Jun;27(6):1795-1806. [Abstract]
- •Cell Death Differ. 2019 Nov;26(11):2400-2415. [Abstract]
- •Theranostics. 2019 Aug 12;9(20):5769-5783. [Abstract]
- •Theranostics. 2019 Aug 14;9(21):6334-6353. [Abstract]
- •Cancer Res. 2019 May 1;79(9):2257-2270. [Abstract]
- •Theranostics. 2019 Apr 13;9(9):2424-2438. [Abstract]
- •EMBO J. 2019 Mar 15;38(6):e100376. [Abstract]
- •J Exp Clin Cancer Res. 2019 Feb 26;38(1):101. [Abstract]
- •J Exp Clin Cancer Res. 2018 Nov 27;37(1):287. [Abstract]
- •J Exp Clin Cancer Res. 2018 Oct 3;37(1):240. [Abstract]
- •J Exp Clin Cancer Res. 2018 Aug 15;37(1):193. [Abstract]
- •EBioMedicine. 2018 Aug;34:243-255. [Abstract]
- •Cancer Res. 2019 Feb 1;79(3):534-545. [Abstract]
- •Nucleic Acids Res. 2018 Apr 20;46(7):3284-3297. [Abstract]
- •Cancer Lett. 2024 Mar 13:216811. [Abstract]
- •Cell Rep. 2024 Mar 1;43(3):113886. [Abstract]
- •Cell Commun Signal. 2024 Mar 7;22(1):168. [Abstract]
- •Int J Biol Macromol. 2024 Mar 26:131151. [Abstract]
- •Cancer Lett. 2024 Feb 13:216732. [Abstract]
- •Cancer Lett. 2024 Feb 8:587:216703. [Abstract]
- •Cancer Lett. 2024 Feb 13:216733. [Abstract]
- •Int J Biol Sci. 2023 Oct 24;19(16):5319-5336. [Abstract]
- •Cell Rep. 2023 Aug 29;42(8):112851. [Abstract]
- •Cell Rep. 2024 Feb 21;43(3):113838. [Abstract]
- •Int J Biol Macromol. 2024 Feb 6;262(Pt 1):130037. [Abstract]
- •Int J Biol Sci. 2024 Jan 12; 20(3):953-967.
- •Br J Cancer. 2024 Jan 16. [Abstract]
- •Metabolism. 2023 Dec 27:155769. [Abstract]
- •Cell Death Dis. 2023 Nov 29;14(11):782. [Abstract]
- •Cell Commun Signal. 2023 Dec 15;21(1):356. [Abstract]
- •Pharmacol Res. 2023 Nov 16:106995. [Abstract]
- •Cell Death Dis. 2023 Nov 25;14(11):765. [Abstract]
- •Cell Rep. 2023 Nov 14;42(11):113426. [Abstract]
- •Cell Rep. 2023 Nov 23;42(12):113479. [Abstract]
- •Cell Chem Biol. 2023 Nov 16:S2451-9456(23)00384-7. [Abstract]
- •Int J Biol Macromol. 2023 Nov 28, 128451.
- •Cancer Lett. 2023 Oct 11:216439. [Abstract]
- •Pharmacol Res. 2023 Oct 20:197:106964. [Abstract]
- •Cell Rep. 2023 Oct 13;42(10):113264. [Abstract]
- •BMC Med. 2023 Sep 25;21(1):366. [Abstract]
- •Cell Death Dis. 2023 Sep 13;14(9):604. [Abstract]
- •Cell Death Dis. 2023 Sep 19;14(9):614. [Abstract]
- •Cell Rep. 2023 Sep 7;42(9):113110. [Abstract]
- •Cell Commun Signal. 2023 Sep 18;21(1):242. [Abstract]
- •Int J Biol Sci. 2023 Jun 26;19(11):3324-3340. [Abstract]
- •Cell Death Dis. 2023 Aug 3;14(8):494. [Abstract]
- •Cell Death Dis. 2023 Aug 25;14(8):558. [Abstract]
- •Cell Rep. 2023 Aug 11;42(8):112975. [Abstract]
- •Cell Rep. 2023 Aug 13;42(8):112968. [Abstract]
- •Cell Commun Signal. 2023 Aug 9;21(1):198. [Abstract]
- •Cancer Lett. 2023 Jun 29;568:216288. [Abstract]
- •Int J Biol Macromol. 2023 Jul 3;125670. [Abstract]
- •Cell Death Dis. 2023 Jun 14;14(6):361. [Abstract]
- •Cell Death Dis. 2023 Jun 13;14(6):360. [Abstract]
- •Cell Commun Signal. 2023 Jun 22;21(1):152. [Abstract]
- •Int J Biol Sci. 2023 May 8;19(8):2531-2550. [Abstract]
- •Int J Biol Sci. 2023 Feb 27;19(5):1471-1489. [Abstract]
- •Cancer Lett. 2023 Apr 4;216158. [Abstract]
- •Eur J Cancer. 2023 Apr 19.
- •Acta Pharmacol Sin. 2023 Apr 13. [Abstract]
- •Cell Death Dis. 2023 Mar 25;14(3):211. [Abstract]
- •Cell Death Dis. 2023 Mar 4;14(3):178. [Abstract]
- •Cell Death Dis. 2023 Mar 11;14(3):193. [Abstract]
- •Cell Rep. 2023 Mar 25;42(4):112309. [Abstract]
- •Pharmacol Res. 2023 Feb 20;189:106704. [Abstract]
- •Cell Death Dis. 2023 Feb 10;14(2):100. [Abstract]
- •Cell Death Dis. 2023 Jan 3;14(1):2. [Abstract]
- •Cell Death Dis. 2023 Jan 5;14(1):6. [Abstract]
- •Cell Rep. 2023 Jan 31;42(1):112002. [Abstract]
- •Cell Rep. 2023 Jan 30;42(2):112033. [Abstract]
- •Clin Immunol. 2023 Jan 20;247:109238. [Abstract]
- •Int J Biol Macromol. 2023 Jan 9;230:123191. [Abstract]
- •Pharmacol Res. 2022 Dec 16;106613. [Abstract]
- •Cell Death Dis. 2022 Dec 12;13(12):1034. [Abstract]
- •Cell Death Dis. 2022 Dec 5;13(12):1021. [Abstract]
- •Int J Biol Macromol. 2022 Dec 3;S0141-8130(22)02877-X. [Abstract]
- •Cell Death Dis. 2022 Nov 28;13(11):1007. [Abstract]
- •Cell Prolif. 2023 Feb;56(2):e13349. [Abstract]
- •Cell Death Dis. 2022 Dec 27;13(12):1075. [Abstract]
- •Cell Death Dis. 2022 Sep 26;13(9):824. [Abstract]
- •Cell Rep. 2022 Oct 25;41(4):111530. [Abstract]
- •Cancer Lett. 2022 Sep 16;215911. [Abstract]
- •Int J Biol Sci. 2022 Jul 18;18(13):4824-4836. [Abstract]
- •Int J Biol Sci. 2022 Aug 29;18(14):5459-5474. [Abstract]
- •Cell Death Dis. 2022 Sep 20;13(9):805. [Abstract]
- •Cell Death Dis. 2022 Aug 29;13(8):742. [Abstract]
- •Cancer Lett. 2022 Aug 8;215862. [Abstract]
- •Cell Death Dis. 2022 Aug 25;13(8):734. [Abstract]
- •Cell Rep. 2022 Aug 16;40(7):111194. [Abstract]
- •Cell Commun Signal. 2022 Aug 15;20(1):121. [Abstract]
- •Cancer Lett. 31 July 2022, 215837.
- •Int J Biol Sci. 2022; 18(10):4245-4259.
- •Cell Death Dis. 2022 Jul 13;13(7):606. [Abstract]
- •Int J Biol Sci. 2022 Jun 21;18(10):4135-4150. [Abstract]
- •Int J Biol Sci. 2022; 18(9):3888-3907.
- •Cell Commun Signal. 2022 Jun 15;20(1):87. [Abstract]
- •PLoS Biol. 2022 Apr 27;20(4):e3001619 [Abstract]
- •Pharmacol Res. 2022 May 13;181:106259. [Abstract]
- •Pharmacol Res. 2022 Jun;180:106244. [Abstract]
- •Int J Biol Sci. 2022 Apr 11;18(7):2932-2948. [Abstract]
- •Int J Biol Sci. 2022 May 1;18(8):3122-3136. [Abstract]
- •Int J Biol Sci. 2022 May 16;18(8):3544-3561. [Abstract]
- •Cell Death Dis. 2022 Apr 22;13(4):396. [Abstract]
- •Cell Death Dis. 2022 Apr 9;13(4):326. [Abstract]
- •Cell Death Dis. 2022 May 3;13(5):427. [Abstract]
- •Cell Death Dis. 2022 May 12;13(5):451. [Abstract]
- •Cell Death Dis. 2022 Apr 25;13(4):403. [Abstract]
- •Cell Death Dis. 2022 May 17;13(5):465. [Abstract]
- •Environ Pollut. 2022 May 22;119484. [Abstract]
- •Cell Rep. 2022 Apr 12;39(2):110656. [Abstract]
- •Cell Death Dis. 2022 Apr 2;13(4):294. [Abstract]
- •Cell Rep. 2022 Apr 12;39(2):110635. [Abstract]
- •Cancer Lett. 2022 Feb 9;532:215588. [Abstract]
- •Cancer Lett. 2022 Feb 4;215586. [Abstract]
- •Pharmacol Res. 2022 Jan 5;106059. [Abstract]
- •Cell Death Dis. 2022 Jan 13;13(1):55. [Abstract]
- •Cell Death Dis. 2022 Jan 10;13(1):42. [Abstract]
- •Cell Rep. 2021 Nov 2;37(5):109949. [Abstract]
- •Cell Mol Biol Lett. 2021 Nov 10;26(1):45. [Abstract]
- •Cell Death Dis. 2021 Sep 25;12(10):878. [Abstract]
- •Cell Death Dis. 2021 Oct 1;12(10):899. [Abstract]
- •Cell Death Dis. 2021 Sep 25;12(10):876. [Abstract]
- •Cell Death Dis. 2021 Oct 20;12(11):968. [Abstract]
- •Cell Rep. 2021 Sep 21;36(12):109739. [Abstract]
- •Cancer Lett. 2021 Jul 30;518:266-277. [Abstract]
- •Cancer Lett. 26 July 2021.
- •Int J Biol Sci. 2021; 17(12): 3013-3023.
- •Cell Rep. 2021 Jul 13;36(2):109384. [Abstract]
- •Cell Death Dis. 2021 Jun 23;12(7):642. [Abstract]
- •Cancer Lett. 2021 May 3;S0304-3835(21)00188-9. [Abstract]
- •New Phytol. 2021 May 27. [Abstract]
- •Cell Death Dis. 2021 May 25;12(6):534. [Abstract]
- •Cell Death Dis. 2021 Apr 12;12(4):388. [Abstract]
- •Int J Biol Macromol. 2021 Apr 14;S0141-8130(21)00832-1. [Abstract]
- •Cell Rep. 2021 Apr 6;35(1):108959.
- •Cell Commun Signal. 2021 Mar 15;19(1):33. [Abstract]
- •Acta Pharmacol Sin. 2021 Feb 11. [Abstract]
- •Cell Death Dis. 2021 Jan 7;12(1):42. [Abstract]
- •Cell Death Dis. 2021 Jan 12;12(1):77. [Abstract]
- •Cell Death Dis. 2020 Nov 26;11(11):1014. [Abstract]
- •Cell Death Dis. 2020 Oct 13;11(10):852. [Abstract]
- •Chemosphere. 2021 Feb;264(Pt 1):128440. [Abstract]
- •Cell Rep. 2020 Aug 4;32(5):107990. [Abstract]
- •Acta Pharmacol Sin. 2020 Aug 11. [Abstract]
- •Cell Rep. 2020 Jul 14;32(2):107877. [Abstract]
- •Cell Rep. 2020 Jul 21;32(3):107936. [Abstract]
- •Cell Chem Biol. 2020 Nov 19;27(11):1359-1370.e8. [Abstract]
- •Pharmacol Res. 2020 Jul;157:104845. [Abstract]
- •Cancer Lett. 2020 Mar 31;473:130-138. [Abstract]
- •Diabetologia. 2020 Apr;63(4):811-824. [Abstract]
- •Cell Prolif. 2019 Nov;52(6):e12689. [Abstract]
- •Cell Death Dis. 2019 Aug 8;10(8):599. [Abstract]
- •Cell Rep. 2019 May.
- •Cell Prolif. 2019 May;52(3):e12606. [Abstract]
- •Cell Rep. 2018 Sep 25;24(13):3513-3527.e7. [Abstract]
- •Cell Prolif. 2018 Aug;51(4):e12451. [Abstract]
- •Cell Death Dis. 2018 May 22;9(6):604. [Abstract]
- •Cancer Lett. 2017 Dec 1;410:112-123. [Abstract]
- •Phytomedicine. 2024 Mar 11, 155527.
- •Phytomedicine. 2024 Mar 20, 155556.
- •Transl Res. 2024 Mar 15:S1931-5244(24)00051-3. [Abstract]
- •Biomed Pharmacother. 2024 Mar 21:174:116447. [Abstract]
- •Breast Cancer Res. 2024 Mar 11;26(1):44. [Abstract]
- •Breast Cancer Res. 2024 Mar 19;26(1):48. [Abstract]
- •PLoS Pathog. 2024 Mar 20;20(3):e1012112. [Abstract]
- •J Agric Food Chem. 2024 Mar 14. [Abstract]
- •Phytomedicine. 2021 Oct:91:153692. [Abstract]
- •PLoS Pathog. 2023 Jul 13;19(7):e1010986. [Abstract]
- •PLoS Pathog. 2024 Feb 14;20(2):e1011981. [Abstract]
- •Mol Oncol. 2022 Mar;16(5):1200-1217. [Abstract]
- •Mbio. 2024 Jan 30:e0343323. [Abstract]
- •Breast Cancer Res. 2024 Jan 2;26(1):1. [Abstract]
- •Sci Signal. 2024 Jan 2;17(817):eadf7318. [Abstract]
- •PLoS Pathog. 2024 Jan 12;20(1):e1011943. [Abstract]
- •Biochim Biophys Acta Mol Basis Dis. 2024 Jan 2:167011. [Abstract]
- •Free Radic Biol Med. 2023 Dec 12:212:162-173. [Abstract]
- •Cell Mol Gastroenterol Hepatol. 2023 Dec 18:S2352-345X(23)00217-5. [Abstract]
- •Cell Death Discov. 2023 Nov 28;9(1):427. [Abstract]
- •Int J Nanomedicine. 2023 Oct 31.
- •Immun Ageing. 2023 Nov 21;20(1):66. [Abstract]
- •J Transl Med. 2023 Nov 21;21(1):838. [Abstract]
- •Cell Death Discov. 2023 Nov 2;9(1):406. [Abstract]
- •Cell Death Discov. 2023 Nov 22;9(1):421. [Abstract]
- •Cell Mol Life Sci. 2023 Oct 13;80(11):325. [Abstract]
- •Oncogene. 2023 Oct 16. [Abstract]
- •Phytomedicine. 122, January 2024, 155156
- •EMBO Rep. 2023 Oct 3:e56614. [Abstract]
- •Mbio. 2023 Oct 26:e0168823. [Abstract]
- •Mbio. 2023 Oct 5:e0211023. [Abstract]
- •J Med Chem. 2023 Aug 31. [Abstract]
- •Cell Death Discov. 2023 Aug 28;9(1):319. [Abstract]
- •PLoS Pathog. 2023 Jul 27;19(7):e1011550. [Abstract]
- •J Med Chem. 2023 Jun 30. [Abstract]
- •Cell Death Discov. 2023 Jun 29;9(1):199. [Abstract]
- •Oncogene. 2023 Jun 13. [Abstract]
- •Phytomedicine. 2023 Jun 8, 154921.
- •EMBO Rep. 2023 Jun 12;e56437. [Abstract]
- •J Transl Med. 2023 Jun 20;21(1):402. [Abstract]
- •Free Radic Biol Med. 2023 Jun 20;205:291-304. [Abstract]
- •Mol Cell Proteomics. 2023 Jun 14;100593. [Abstract]
- •Phytomedicine. 2023 May 12, 154876.
- •Antiviral Res. 2023 May 23;105641. [Abstract]
- •Antiviral Res. 2023 May 6;105621. [Abstract]
- •Breast Cancer Res. 2023 May 22;25(1):55. [Abstract]
- •Free Radic Biol Med. 2023 May 27;S0891-5849(23)00446-X. [Abstract]
- •J Transl Med. 2023 May 5;21(1):306. [Abstract]
- •Apoptosis. 2023 May 6. [Abstract]
- •J Cell Biol. 2023 May 1;222(5):e202103098. [Abstract]
- •Free Radic Biol Med. 2023 Apr 10;S0891-5849(23)00373-8. [Abstract]
- •Oncogene. 2023 Mar 7. [Abstract]
- •Biomed Pharmacother. 2023 Mar 18;161:114560. [Abstract]
- •Free Radic Biol Med. 2023 Mar 18;S0891-5849(23)00118-1. [Abstract]
- •Plant Physiol. 2023 Mar 22;kiad188. [Abstract]
- •J Med Chem. 2023 Mar 9. [Abstract]
- •Cancer Gene Ther. 2023 Mar 17. [Abstract]
- •Life Sci. 2023 Mar 17;121594. [Abstract]
- •Life Sci. 2023 Mar 21;121608. [Abstract]
- •Cell Biosci. 2023 Feb 21;13(1):37. [Abstract]
- •Br J Pharmacol. 2023 Feb 14. [Abstract]
- •J Lipid Res. 2023 Feb 8;100342. [Abstract]
- •Oncogenesis. 2023 Feb 4;12(1):3. [Abstract]
- •Oncogene. 2023 Jan 5. [Abstract]
- •Apoptosis. 2023 Jan 25. [Abstract]
- •Cell Biosci. 2022 Dec 19;12(1):203. [Abstract]
- •Antioxidants (Basel). 2023, 12(1), 74.
- •Mol Oncol. 2022 Dec 22. [Abstract]
- •Oncogene. 2022 Nov 8. [Abstract]
- •Free Radic Biol Med. 2022.
- •Apoptosis. 2022 Nov 27. [Abstract]
- •Cell Oncol. 2022 Nov 4. [Abstract]
- •Elife. 2022 Oct 7;11:e80760. [Abstract]
- •Cell Biosci. 2022 Oct 8;12(1):169. [Abstract]
- •Oncogene. 2022 Aug 30. [Abstract]
- •Cell Death Discov. 2022 Sep 16;8(1):386. [Abstract]
- •Mbio. 2022 Sep 15;e0143422. [Abstract]
- •Free Radic Biol Med. 2022 Aug 5;S0891-5849(22)00508-1. [Abstract]
- •Oncogene. 2022 Jun 30. [Abstract]
- •Cancer Gene Ther. 2022 Jul 28. [Abstract]
- •Br J Pharmacol. 2022 Jun 21. [Abstract]
- •Antioxid Redox Signal. 2022 Jun 16. [Abstract]
- •J Transl Med. 2022 May 4;20(1):191. [Abstract]
- •Cell Death Discov. 2022 May 17;8(1):265. [Abstract]
- •Liver Int. 2022 Apr 22. [Abstract]
- •Free Radic Biol Med. 2022 Mar 3;S0891-5849(22)00081-8. [Abstract]
- •Cell Death Discov. 2022 Mar 9;8(1):107. [Abstract]
- •Oncogene. 2022 Feb 10. [Abstract]
- •Aging Cell. 2022 Feb 23;e13573. [Abstract]
- •Phytother Res. 2022 Feb 7. [Abstract]
- •Phytother Res. 2022 Feb;36(2):938-950. [Abstract]
- •Cell Death Discov. 2022 Feb 11;8(1):59. [Abstract]
- •Mbio. 2022 Jan 25;13(1):e0233021. [Abstract]
- •Free Radic Biol Med. 14 January 2022.
- •Free Radic Biol Med. 16 January 2022.
- •Breast Cancer Res. 2021 Dec 18;23(1):116. [Abstract]
- •Cell Death Discov. 2021 Dec 8;7(1):379. [Abstract]
- •Cell Death Discov. 2021 Dec 14;7(1):389. [Abstract]
- •Ecotoxicol Environ Saf. 25 December 2021, 113028.
- •Life Sci. 2021 Dec 16;289:120231. [Abstract]
- •Phytomedicine. 20 November 2021, 153861.
- •Diabetes. 2021 Oct 21;db210240. [Abstract]
- •Br J Pharmacol. 2021 Sep 22. [Abstract]
- •Oncogene. 2021 Sep 23. [Abstract]
- •PLoS Pathog. 2021 Sep 13;17(9):e1009900. [Abstract]
- •Biochim Biophys Acta Mol Basis Dis. 2021 Jul 23;166213. [Abstract]
- •PLoS Pathog. 2021 Jun 2;17(6):e1009645. [Abstract]
- •Phytomedicine. 2021, 153578.
- •Life Sci. 2021 Apr 28;119552. [Abstract]
- •Free Radic Biol Med. 2021 Apr 22;S0891-5849(21)00265-3. [Abstract]
- •NPJ Precis Oncol. 2021 Mar 2;5(1):14. [Abstract]
- •Free Radic Biol Med. 2021 Mar 21;S0891-5849(21)00168-4. [Abstract]
- •J Pathol. 2021 Feb 27. [Abstract]
- •PLoS Pathog. 2021 Mar 4;17(3):e1009370. [Abstract]
- •Phytomedicine. 2021, 153503.
- •Diabetes. 2021 Feb 24;db201008. [Abstract]
- •Cancer Gene Ther. 2021 Feb 8. [Abstract]
- •Mol Ther-Nucl Acids. 2021 Jan 26.
- •Cell Biosci. 2020 Dec 22;10(1):146. [Abstract]
- •Cell Biosci. 2020 Nov 27;10(1):139. [Abstract]
- •Oncogene. 2021 Jan;40(1):163-176. [Abstract]
- •Phytomedicine. 2021 Jan;80:153383. [Abstract]
- •Biomed Pharmacother. 2020 Dec;132:110856. [Abstract]
- •Cell Oncol. 2021 Apr;44(2):329-343. [Abstract]
- •Free Radic Biol Med. 2020 Nov 20;160:303-318. [Abstract]
- •Free Radical Bio Med. 2020 Nov 1;159:164-176. [Abstract]
- •Eur J Med Chem. 2020 Nov 15;206:112708. [Abstract]
- •Life Sci. 2020 Sep 15;257:118021. [Abstract]
- •Elife. 2020 Jun 2;9:e54954. [Abstract]
- •Ecotoxicol Environ Saf. 2020 Sep 15;201:110831. [Abstract]
- •Life Sci. 2020 Sep 1;256:117983. [Abstract]
- •Biomed Pharmacother. 2020 Aug;128:110221. [Abstract]
- •Oncogenesis. 2020 Apr 29;9(4):42. [Abstract]
- •Plant Physiol. 2020 May;183(1):358-370. [Abstract]
- •Oncogenesis. 2020 Mar 12;9(3):34. [Abstract]
- •J Invest Dermatol. 2020 Oct;140(10):2009-2022.e4. [Abstract]
- •Life Sci. 2020 Apr 1;246:117419. [Abstract]
- •Mol Ther Nucleic Acids. 2020 Mar 6;19:974-985. [Abstract]
- •Gene Dis. 2019 May 25;7(3):401-407. [Abstract]
- •Free Radic Biol Med. 2020 May 20;152:525-539. [Abstract]
- •Int J Cancer. 2020 Apr 1;146(7):1963-1978. [Abstract]
- •J Exp Bot. 2019 Sep 24;70(18):4749-4762. [Abstract]
- •Antioxid Redox Signal. 2019 May 20;30(15):1831-1848. [Abstract]
- •JCI Insight. 2019 Feb 21;4(4). pii: 121582. [Abstract]
- •Aging Cell. 2020 Jul;19(7):e13171. [Abstract]
- •Eur J Med Chem. 2018 Feb 1;146:251-259. [Abstract]
- •Blood Adv. 2017 Sep 8;1(20):1773-1785. [Abstract]
- •Acta Neuropathol Commun. 2017 Sep 6;5(1):67. [Abstract]
- •iScience. 2024 Mar 9.
- •J Cell Physiol. 2024 Mar 22. [Abstract]
- •BMC Biol. 2024 Mar 25;22(1):71. [Abstract]
- •Am J Cancer Res. 2024 Feb 15;14(2):727-743. [Abstract]
- •J Biol Chem. 2024 Mar 8:107152. [Abstract]
- •Biochem Pharmacol. 2024 Feb 3:221:116040. [Abstract]
- •iScience. 2024 Feb 13.
- •Front Pharmacol. 2023 Apr 18:14:1148611. [Abstract]
- •J Virol. 2024 Feb 20;98(2):e0190923. [Abstract]
- •Cell Signal. 2024 Feb 1:117:111070. [Abstract]
- •Toxicology. 2024 Feb 6:503:153742. [Abstract]
- •iScience. 2024 Jan 17.
- •Virol Sin. 2024 Jan 23:S1995-820X(24)00005-1. [Abstract]
- •J Biol Chem. 2024 Jan 23:105673. [Abstract]
- •Virulence. 2024 Dec;15(1):2289764. [Abstract]
- •Chem Commun. 2023 Dec 6. [Abstract]
- •iScience. 2023 Nov 15.
- •Cancer Cell Int. 2023 Nov 21;23(1):286. [Abstract]
- •Mol Nutr Food Res. 2023 Oct 28:e2300444. [Abstract]
- •Biochem Pharmacol. 2023 Sep 29:115834. [Abstract]
- •Mol Med. 2023 Oct 20;29(1):139. [Abstract]
- •Int J Mol Sci. 2023 Sep 26;24(19):14530. [Abstract]
- •Cancers (Basel). 2023 Oct 18, 15(20), 5033.
- •Fish Shellfish Immunol. 2023 Oct 5:142:109145. [Abstract]
- •ACS Pharmacol Transl Sci. 2023 Sep 1.
- •CNS Neurosci Ther. 2023 Aug 29. [Abstract]
- •Virol Sin. 2023 Sep 13;S1995-820X(23)00110-4. [Abstract]
- •Am J Cancer Res. 2023 Aug 15;13(8):3705-3720. [Abstract]
- •Cancers (Basel). 2023 Sep 1;15(17):4385. [Abstract]
- •J Biol Chem. 2023 Sep 1;105215. [Abstract]
- •Mol Carcinog. 2023 Sep 22. [Abstract]
- •Int J Mol Sci. 2023 Aug 13, 24(16), 12740.
- •J Virol. 2023 Aug 11;e0018123. [Abstract]
- •Biochim Biophys Acta Mol Cell Res. 2023 Aug 4;119556. [Abstract]
- •Poult Sci. 2023 Aug 15, 103026.
- •J Hepatocell Carcinoma. 2023 Aug 3.
- •iScience. 2023 Jun 21.
- •Mol Med. 2023 Jul 6;29(1):91. [Abstract]
- •J Cell Physiol. 2023 Jul 21. [Abstract]
- •J Cell Mol Med. 2023 Jul 17. [Abstract]
- •Int J Oncol. 2023 Aug;63(2):98.
- •J Biol Chem. 2023 Jun 29;104994. [Abstract]
- •FASEB J. 2023 Aug;37(8):e23083. [Abstract]
- •Fish Shellfish Immunol. 2023 Jul 23;108965. [Abstract]
- •Viruses. 2023 Jul 28, 15(8), 1644.
- •Am J Pathol. 2023 Jun 8;S0002-9440(23)00204-3. [Abstract]
- •J Virol. 2023 Jun 8;e0038223. [Abstract]
- •Biochim Biophys Acta Mol Cell Res. 2023 Jun 23;119527. [Abstract]
- •Cell Signal. 2023 Jun 2;110744. [Abstract]
- •Cell Signal. 2023 Jun 1;110739. [Abstract]
- •J Proteome Res. 2023 Jun 7. [Abstract]
- •Biochem Pharmacol. 2023 May 3;115581. [Abstract]
- •iScience. 2023 May 5.
- •Clin Epigenetics. 2023 May 5;15(1):77. [Abstract]
- •J Biol Chem. 2023 May 11;104814. [Abstract]
- •J Biol Chem. 2023 May 16, 104829.
- •Int J Mol Sci. 2023 Apr 6, 24(7), 6826.
- •J Biol Chem. 2023 Apr 17;104723. [Abstract]
- •Vet Res. 2023 Apr 2;54(1):30. [Abstract]
- •Biochem Pharmacol. 2023 Mar 7;115489. [Abstract]
- •J Nutr Biochem. 2023 Mar 27;109337. [Abstract]
- •J Mol Cell Biol. 2023 Mar 22;mjad019. [Abstract]
- •J Virol. 2023 Mar 21;e0026423. [Abstract]
- •J Virol. 2023 Mar 6;e0198422. [Abstract]
- •J Biol Chem. 2023 Mar 17;104621. [Abstract]
- •FASEB J. 2023 Apr;37(4):e22848. [Abstract]
- •iScience. 2023 Feb.
- •Int J Mol Sci. 2023 Feb 3;24(3):2960. [Abstract]
- •J Ethnopharmacol. 2023 Feb 13;307:116243. [Abstract]
- •J Virol. 2023 Feb 6;e0133822. [Abstract]
- •Int J Oncol. 2023 Mar;62(3):40. [Abstract]
- •Chem Biol Interact. 2023 Feb 21;110408. [Abstract]
- •J Biol Chem. 2023 Feb 7;102990. [Abstract]
- •FASEB J. 2023 Mar;37(3):e22832. [Abstract]
- •J Neurosci. 2023 Jan 17;JN-RM-1209-22. [Abstract]
- •Biochim Biophys Acta Mol Cell Res. 2023 Jan 24;1870(3):119433. [Abstract]
- •J Immunol. 2023 Jan 30;ji2200544. [Abstract]
- •J Neurosci Res. 2023 Jan 31. [Abstract]
- •Mech Ageing Dev. 2022: 111760.
- •Nutrients. 2022, 14(23), 5044.
- •Biochem Pharmacol. 2022 Nov 25;115355. [Abstract]
- •Eur J Pharmacol. 2022 Nov 24;175411. [Abstract]
- •Biochem Pharmacol. 2022 Oct 29;206:115326. [Abstract]
- •J Neurosci. 2022 Jun 22;42(25):4958-4979. [Abstract]
- •Neoplasia. 2022 Oct 11;34:100839. [Abstract]
- •Front Oncol. 2022 Sep 23;12:868866. [Abstract]
- •Stem Cells Int. 0 Sept 2022.
- •Int J Mol Sci. 2022, 23(19), 11048.
- •Int J Mol Sci. 2022 Sep 5;23(17):10161. [Abstract]
- •Front Pharmacol. 17 August 2022.
- •J Cell Mol Med. 2022 Sep 7. [Abstract]
- •J Innate Immun. 2022 Sep 16;1-18. [Abstract]
- •Neoplasia. 2022 Nov;33:100835. [Abstract]
- •Mol Ther Oncolytics. 25 August 2022.
- •J Virol. 2022 Sep 14;96(17):e0094422. [Abstract]
- •Front Mol Biosci. 22 July 2022.
- •iScience. 20 July 2022, 104773.
- •J Virol. 2022 Jul 19;e0080722. [Abstract]
- •Vet Res. 2022 Jul 8;53(1):55. [Abstract]
- •iScience. 2022 Jun 7;25(7):104544. [Abstract]
- •Inflammation. 2022 Dec;45(6):2309-2324. [Abstract]
- •iScience. 2022 May 18;25(6):104416. [Abstract]
- •Biochem Pharmacol. 2022 May 25;115107. [Abstract]
- •Front Pharmacol. 2022 May 20;13:911945. [Abstract]
- •Am J Cancer Res. 2022 Mar 15;12(3):1069-1087. [Abstract]
- •Chem Biol Interact. 2022 May 30;109999. [Abstract]
- •Commun Biol. 2022 Mar 1;5(1):182. [Abstract]
- •J Cell Mol Med. 2022 Mar 9. [Abstract]
- •Virulence. 2022 Dec;13(1):514-529. [Abstract]
- •Biochem Pharmacol. 2022 Feb 21;114975. [Abstract]
- •Eur J Pharmacol. 2022 Feb 11;920:174822. [Abstract]
- •Transl Oncol. 2022 Apr;18:101362. [Abstract]
- •Commun Biol. 2021 Dec 13;4(1):1391. [Abstract]
- •Cancer Cell Int. 2022 Jan 6;22(1):7. [Abstract]
- •Front Cell Dev Biol. 2021 Dec 24;9:781792. [Abstract]
- •J Cell Mol Med. 2021 Dec 28. [Abstract]
- •Chem Biol Interact. 2022 Jan 5;109798. [Abstract]
- •Lab Invest. 2022 Jan 10. [Abstract]
- •Lab Invest. 2022 Jan 18. [Abstract]
- •Cancer Cell Int. 2021 Nov 27;21(1):631. [Abstract]
- •Environ Toxicol. 2021 Dec 7. [Abstract]
- •Food Chem Toxicol. 2021 Dec 14;112771. [Abstract]
- •Front Pharmacol. 2021 Oct 18;12:709526. [Abstract]
- •Inflammation. 2021 Nov 27. [Abstract]
- •Lab Invest. 2021 Nov 13. [Abstract]
- •Neoplasia. 2021 Nov 8;23(12):1227-1239. [Abstract]
- •Front Cell Infect Microbiol. 2021 Aug 12;11:662404. [Abstract]
- •Front Pharmacol. 2021 Mar 22;12:572463. [Abstract]
- •J Ethnopharmacol. 2021 Sep 30;114694. [Abstract]
- •Front Cell Neurosci. 2021 Mar 18;15:569424. [Abstract]
- •Chem Biol Interact. 2021 Oct 27;109729. [Abstract]
- •Bioengineered. 2021 Oct 26. [Abstract]
- •J Biol Chem. 15 October 2021, 101307.
- •Front Oncol. 2021 Feb 23;11:615568. [Abstract]
- •Oncol Rep. 2021 Dec;46(6):253. [Abstract]
- •Aging (Albany NY). 2021 Sep 8;13(17):21547-21570. [Abstract]
- •Mol Ther Oncolytics. 28 August 2021.
- •Int J Mol Med. August 20, 2021.
- •Mol Nutr Food Res. 2021 Jul 30;e2100367. [Abstract]
- •Gene Ther. 2021 Aug 20. [Abstract]
- •Front Cell Dev Biol. 2021 Feb 5;8:621509. [Abstract]
- •J Cell Mol Med. 2021 Jun 29. [Abstract]
- •Cancers (Basel). 2021 Jul 11;13(14):3467. [Abstract]
- •Am J Cancer Res. 2021 May 15;11(5):2238-2251. [Abstract]
- •Transl Oncol. 2021 Sep;14(9):101148. [Abstract]
- •Int Immunopharmacol. 2021 Apr 28;97:107688. [Abstract]
- •J Cell Mol Med. 2021 May 4. [Abstract]
- •Front Cell Dev Biol. 30 March 2021.
- •ACS Chem Neurosci. 2021 Apr 5. [Abstract]
- •J Biol Chem. 2021, 100616.
- •Cell Signal. 2021 Apr 3;110002. [Abstract]
- •Mar Drugs. 2021 Jan 31;19(2):79. [Abstract]
- •Oncol Rep. 2021 Feb 3.
- •FEBS J. 2021 Jan 25. [Abstract]
- •Mol Neurobiol. 2021 Jan 7. [Abstract]
- •Cancer Cell Int. 2020 Dec 7;20(1):587. [Abstract]
- •J Cell Mol Med. 2020 Dec;24(23):14039-14049. [Abstract]
- •Am J Pathol. 2020 Dec;190(12):2464-2477. [Abstract]
- •Virus Res. 2021 Jan 2;291:198220. [Abstract]
- •Arthritis Res Ther. 2020 Nov 16;22(1):269. [Abstract]
- •J Cell Mol Med. 2020 Dec;24(24):14171-14183. [Abstract]
- •Aging. 2020 Oct 25;12(20):20047-20068. [Abstract]
- •J Cell Mol Med. 2020 Nov;24(22):12994-13009. [Abstract]
- •J Cell Mol Med. 2020 Oct;24(19):11512-11523. [Abstract]
- •J Biol Chem. 2020 Dec 4;295(49):16826-16839. [Abstract]
- •J Biol Chem. 2020 Oct 2;295(40):13798-13811. [Abstract]
- •Am J Cancer Res. 2020 Oct 1;10(10):3440-3457. [Abstract]
- •J Zhejiang Univ Sci B. 2020 Jul;21(7):560-570. [Abstract]
- •J Cell Physiol. 2020 Dec;235(12):9538-9556. [Abstract]
- •Front Microbiol. 2020 May 20;11:987. [Abstract]
- •FASEB J. 2020 Aug;34(8):10966-10983. [Abstract]
- •Front Pharmacol. 2020 May 8;11:668. [Abstract]
- •J Cell Physiol. 2020 Nov;235(11):8546-8557. [Abstract]
- •Front Cell Dev Biol. 2020 May 7;8:287. [Abstract]
- •Cell Signal. 2020 Aug;72:109654. [Abstract]
- •FASEB J. 2020 Jun;34(6):7631-7643. [Abstract]
- •Food Chem Toxicol. 2020 Jun;140:111329. [Abstract]
- •J Nat Prod. 2020 Apr 24;83(4):1217-1228. [Abstract]
- •Bone. 2020 Jun;135:115326. [Abstract]
- •Biochem Pharmacol. 2020 May;175:113856. [Abstract]
- •Mol Cancer Res. 2020 Feb;18(2):204-215. [Abstract]
- •Front Microbiol. 2020 Jan 8;10:3040. [Abstract]
- •Viruses. 2019 Dec 30;12(1):43. [Abstract]
- •Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2882-2890. [Abstract]
- •Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2343-2351. [Abstract]
- •Biochem Pharmacol. 2020 Jan;171:113715. [Abstract]
- •Int J Oncol. 2020 Jan;56(1):232-242. [Abstract]
- •Viruses. 2019 Nov 30;11(12):1112. [Abstract]
- •J Biol Chem. 2019 Nov 29;294(48):18504-18515. [Abstract]
- •Mol Cancer Ther. 2020 Jan;19(1):221-230. [Abstract]
- •J Biol Chem. 2019 Jul 19;294(29):11119-11130. [Abstract]
- •Cell Signal. 2019 Feb;54:17-26. [Abstract]
- •Molecules. 2019 Jan 22;24(3):393. [Abstract]
- •Mol Plant Pathol. 2018 Dec;19(12):2623-2634. [Abstract]
- •Biochem Pharmacol. 2018 Oct;156:511-523. [Abstract]
- •Aging (Albany NY). 2018 Oct 18;10(10):2783-2799. [Abstract]
- •Cell Cycle. 2018;17(13):1591-1601. [Abstract]
- •Biochem Pharmacol. 2018 Apr;150:280-292. [Abstract]
- •Front Pharmacol. 2018 Apr 19;9:377. [Abstract]
- •Sci Rep. 2017 Jul 5;7(1):4738. [Abstract]
- •Sci Rep. 2017 Jun 7;7(1):2929. [Abstract]
- •Biochem Biophys Res Commun. 2024 Mar 16, 149798.
- •Oral Dis. 2024 Feb 20. [Abstract]
- •Exp Cell Res. 2024 Mar 1;436(1):113956. [Abstract]
- •Oncol Lett. 2024 Jan 5.
- •BMC Med Genomics. 2024 Jan 26;17(1):36. [Abstract]
- •Biochem Genet. 2024 Jan 12. [Abstract]
- •Microbiol Spectr. 2023 Nov 29:e0312423. [Abstract]
- •Gene. 2023 Dec 15:897:148085. [Abstract]
- •J Ovarian Res. 2023 Nov 25;16(1):229. [Abstract]
- •Kaohsiung J Med Sci. 2023 Nov 23. [Abstract]
- •Biochem Biophys Res Commun. 2023 Nov 25, 149324.
- •Exp Cell Res. 2023 Oct 13:113805. [Abstract]
- •Kaohsiung J Med Sci. 2023 Oct 24. [Abstract]
- •Ann Hematol. 2023 Sep 9. [Abstract]
- •Neuroscience. 2023 Sep 1;S0306-4522(23)00405-0. [Abstract]
- •Cancer Biol Ther. 2023 Dec 31;24(1):2230641. [Abstract]
- •Heliyon. 2023 Jun 8.
- •Arch Biochem Biophys. 2023 May 17;109640. [Abstract]
- •Arch Biochem Biophys. 2023 May 19;109642. [Abstract]
- •Toxicol Appl Pharmacol. 2023 May 26;116568. [Abstract]
- •Exp Cell Res. 2023 May 19;113644. [Abstract]
- •Vet Microbiol. 2023 Apr 29;282:109767. [Abstract]
- •Exp Cell Res. 2023 Apr 10;113587. [Abstract]
- •Exp Cell Res. 2023 Apr 11;427(1):113601. [Abstract]
- •Tissue Eng Regen Med. 2023 Apr 3. [Abstract]
- •Exp Ther Med. 2023 25: 224.
- •Cell Biol Int. 2023 Mar 8. [Abstract]
- •J Pharm Pharmacol. 2023 Mar 27;rgad018. [Abstract]
- •J Oral Pathol Med. 2023 Mar 19. [Abstract]
- •Anal Cell Pathol. 2023 Mar 28.
- •Insects. 2023 Mar 23.
- •PLoS One. 2023 Feb 7;18(2):e0281536. [Abstract]
- •Vet Microbiol. 2023 Jan 24;279:109666. [Abstract]
- •Biochem Bioph Res Co. 2023.
- •ACS Chem Biol. 2022 Dec 16;17(12):3389-3406. [Abstract]
- •Toxicol Sci. 2022 Dec 19;kfac133. [Abstract]
- •Med Oncol. 2022 Dec 28;40(1):63. [Abstract]
- •Clin Exp Metastasis. 2022 Nov 5. [Abstract]
- •Am J Reprod Immunol. 2022 Nov 22;e13659. [Abstract]
- •Eur J Neurosci. 2022 Nov 28. [Abstract]
- •Pathol Int. 2022 Oct 26. [Abstract]
- •ACS Chem Biol. 2022 Sep 8. [Abstract]
- •Clin Transl Oncol. 2022 Sep 22. [Abstract]
- •Biochem Biophys Res Commun. 31 August 2022.
- •Cancer Med. 2022 May 2. [Abstract]
- •Arch Biochem Biophys. 2022 May 22;725:109299. [Abstract]
- •J Cancer. 2022 Mar 28;13(7):2061-2073. [Abstract]
- •Arch Biochem Biophys. 2022 May 30;721:109194. [Abstract]
- •Gene. 2022 Jul 20;832:146559. [Abstract]
- •Prostate. 2022 Jun;82(8):917-932. [Abstract]
- •Int J Med Sci. 2022 Mar 6;19(3):525-536. [Abstract]
- •J Cardiovasc Transl Res. 2022 Mar 2. [Abstract]
- •Int J Med Sci. 2022 Jan 1;19(2):274-285. [Abstract]
- •FEBS Lett. 2022 Apr;596(7):924-937. [Abstract]
- •Cytokine. 2022 Jan 5;151:155789. [Abstract]
- •Metab Brain Dis. 2022 Feb;37(2):329-341. [Abstract]
- •Hum Mol Genet. 2022 Jan 12;ddac008. [Abstract]
- •Biochem Biophys Res Commun. 13 January 2022.
- •J Cell Sci. 2021 Dec 3;jcs.258910. [Abstract]
- •J Cancer. 2022; 13(2):641-652.
- •Exp Cell Res. 2022 Jan 1;410(1):112955. [Abstract]
- •Neurotoxicology. 2021 Dec 10;S0161-813X(21)00166-2. [Abstract]
- •BMC Cancer. 2021 Nov 5;21(1):1181. [Abstract]
- •Appl Biochem Biotechnol. 2021 Nov 26. [Abstract]
- •Front Physiol. 2021 Feb 19;12:609674. [Abstract]
- •BMC Cancer. 2021 Oct 13;21(1):1101. [Abstract]
- •Exp Cell Res. 12 October 2021, 112868.
- •Exp Cell Res. 28 August 2021, 112799.
- •Mol Med Rep. July 5, 2021.
- •BMC Pulm Med. 2021 Nov 22;21(1):379. [Abstract]
- •Arch Insect Biochem Physiol. 2021 Jun 1;e21823. [Abstract]
- •J Pharmacol Sci. 2021 May 11.
- •Hum Exp Toxicol. 2021 May 18;9603271211017972. [Abstract]
- •Exp Cell Res. 2021 Mar 9;112552. [Abstract]
- •Microb Pathog. 2021 Feb 8;153:104788. [Abstract]
- •Int J Med Sci. 2021 Jan 1;18(1):245-255. [Abstract]
- •J Gastrointest Oncol. 2020 Dec;11(6):1200-1213. [Abstract]
- •FEBS Open Bio. 2021 Feb;11(2):456-467. [Abstract]
- •Drug Dev Res. 2021 May;82(3):422-429. [Abstract]
- •Med Oncol. 2020 Nov 19;37(12):116. [Abstract]
- •Cancer Manag Res. 2020 Nov 6;12:11371-11382. [Abstract]
- •FEBS Lett. 2021 Jan;595(2):169-182. [Abstract]
- •Exp Ther Med. 2020 Dec;20(6):249. [Abstract]
- •Clin Oral Investig. 2020 Oct 2. [Abstract]
- •Toxicol In Vitro. 2020 Dec;69:104971. [Abstract]
- •J Alzheimers Dis. 2020;76(2):491-504. [Abstract]
- •J Alzheimers Dis. 2020;76(2):623-641. [Abstract]
- •Int J Med Sci. 2020 Jun 29;17(11):1652-1664. [Abstract]
- •Biochem Biophys Res Commun. 2020 Feb 18;S0006-291X(20)30325-9. [Abstract]
- •Biochem Biophys Res Commun. 2020 Apr 2;524(2):280-287. [Abstract]
- •Int J Biochem Cell Biol. 2020 Jan;118:105644. [Abstract]
- •Toxicol Appl Pharmacol. 2019 Oct 1;380:114696. [Abstract]
- •FEBS Lett. 2020 Feb;594(3):497-508. [Abstract]
- •Vet Microbiol. 2019 Dec;239:108456. [Abstract]
- •Exp Eye Res. 2019 Nov;188:107782. [Abstract]
- •Biochem Biophys Res Commun. 2019 Sep 17;517(2):376-382. [Abstract]
- •PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- •Insect Mol Biol. 2020 Feb;29(1):104-111. [Abstract]
- •Biochem Biophys Res Commun. 2019 Feb 12;509(3):797-802. [Abstract]
- •Mol Immunol. 2018 Nov 13;104:69-78. [Abstract]
- •Oncol Lett. 2018 Nov;16(5):5900-5906. [Abstract]
- •J Cell Sci. 2018 Jun 11;131(11). pii: jcs216598. [Abstract]
- •J Inorg Biochem. 2017 Oct;175:92-100. [Abstract]
- •Biochem Biophys Res Commun. 2017 Sep 2;490(4):1168-1175. [Abstract]
- •Can J Physiol Pharmacol. 2017 May;95(5):481-491. [Abstract]
- •Can J Physiol Pharmacol. 2017 May;95(5):481-491. [Abstract]
- •Biochem Biophys Res Commun. 2016 Apr 29;473(2):396-402. [Abstract]
- •Cell J. 2023 Feb 1;25(2):118-125. [Abstract]
- •Transl Cancer Res. 2024 Jan 29.
- •J Cardiothorac Surg. 2023 Mar 24;18(1):92. [Abstract]
- •Psychogeriatrics. Psychogeriatrics [Abstract]
- •Transl Cancer Res. 2019 Oct;8(6):2449-2460. [Abstract]
- •Asian Pac J Trop Bio. 2020;10:224-31.
- •Transl Cancer Res. 2019;8(6):2449-2460.
- •Research Square Preprint. 2024 Mar 19.
- •bioRxiv. 2024 Feb 7.
- •Research Square Preprint. 2024 Jan 2.
- •Research Square Preprint. 2023 Dec 29.
- •bioRxiv. 2023 Dec 20.
- •Research Square Preprint. 2023 Oct 31.
- •SSRN. 2023 Oct 12.
- •bioRxiv. 2023 Sep 28.
- •Research Square Preprint. 2023 Oct 3.
- •bioRxiv. 2023 Oct 4.
- •SSRN. 2023 Sep 5.
- •SSRN. 2023 Sep 27.
- •Research Square Preprint. 2023 Sep 11.
- •SSRN. 2023 Sep 18.
- •SSRN. 2023 Aug 1.
- •Research Square Preprint. 2023 Aug 28.
- •Research Square Preprint. 2023 Jul 31.
- •Research Square Preprint. 2023 Aug 1.
- •Research Square Preprint. 2023 Aug 4.
- •SSRN. 2023 Aug 4.
- •SSRN. 2023 Jul 28.
- •Research Square Preprint. 2023 Jun 26.
- •Research Square Preprint. 2023 Jun 22.
- •bioRxiv. 2023 Jun 5.
- •Research Square Preprint. 2023 Jun 1.
- •SSRN. 2023 Jun 22.
- •Research Square Preprint. 2023 May 4.
- •Discov Oncol. 2023 May 27;14(1):83. [Abstract]
- •Research Square Preprint. 2023 May 26.
- •Research Square Preprint. 2023 May 8.
- •Research Square Preprint. 2023 May 24.
- •Research Square Preprint. 2023 May 22.
- •bioRxiv. 2023 May 1.
- •Research Square Preprint. 2023 Apr 11.
- •Research Square Print. 2023 Mar 24.
- •bioRxiv. 2023 Mar 18.
- •Research Square Print. 2023 Mar 17.
- •Research Square Print. 2023 Feb 9th.
- •Research Square Print. 2023 Feb 3.
- •Research Square Print. 2023 Feb 21.
- •J Oncol. 2023 Jan.
- •Research Square Print. 2023 Jan 24.
- •Research Square Print. 2023 Jan 9.
- •Research Square Print. November 30th, 2022.
- •Research Square Print. December 1st, 2022.
- •. November 29th, 2022.
- •Research Square Print. November 29th, 2022.
- •SSRN. 7 Nov 2022
- •Research Square Print. October 13th, 2022.
- •Research Square Print. October 10th, 2022.
- •Research Square Print. October 25th, 2022.
- •J Recept Signal Transduct Res. 2022 Aug 31;1-11. [Abstract]
- •Research Square Print. September 9th, 2022.
- •Research Square Print. 2022 Aug.
- •Research Square Print. 2022 Jul.
- •Research Square Preprint. 2022 May.
- •Research Square Preprint. 2022 Feb.
- •Chemrxiv. Feb 03, 2022.
- •University of Coruña. Facultade de Ciencias. 2022 Jan.
- •Research Square Preprint. 2022 Jan.
- •Research Square Preprint. 2021 Aug.
- •Research Square Preprint. 2021 Jul.
- •Research Square Preprint. 2021 May.
- •Research Square Preprint. 2021 Jan.
- •Research Square Preprint. 2020 Nov.
- •Ann Transl Med. 2020 Oct;8(20):1304. [Abstract]
- •bioRxiv. 2020 Jul.
- •bioRxiv. 2020 Jun.
- •bioRxiv. 2020 Jan.
- •Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3322-3338. [Abstract]
- •Biology, Preclinical Medicine. University Regensburg. 2018 Jun.
- •Université de Montréal. Octobre 2017.
- •Oncotarget. 2016 May 10;7(19):27176-84. [Abstract]
- •Harvard Medical School LINCS LIBRARY
-
MG-132 purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2023 Feb 20;189:106704. [Abstract]
- MG132 (10 µM) significantly reduces the degradation of YTHDC1 protein mediated by Dihydroartemisinin (DHA) in HSCs.
-
MG-132 purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2023 Feb 13;307:116243. [Abstract]
- Both MG-132 (10 μM) and Baf A1 (10 μM) markedly increase TGF-β1 protein expression in HG-stimulated SV40-MES-13 cells (Fig. C and D).
-
MG-132 purchased from MedChemExpress. Usage Cited in: J Virol. 2023 Mar 6;e0198422. [Abstract]
- MG-132 (200 nM; 24 h) significantly inhibits Newcastle disease virus (NDV) infection-caused degradation of β-catenin in DF-1 cells.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2020 Aug 4;32(5):107990. [Abstract]
- PMs are treated with MG132 (10 μM). Endogenous YAP protein accumulated in the presence of MG132 starts from 2 h and further increases at 4 and 6 h after treatment in WT macrophages.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2019 Jul;79:244-255. [Abstract]
- Effect of autolysosome inhibitor (chloroquine, CQ, 50 μM) or proteasome inhibitor (MG132, 5 μM) on KA-induced NLRP3 degradation. Cells are treated with the inhibitors for 0.5 h before KA (10 μM, 2 h) treatment.
-
MG-132 purchased from MedChemExpress. Usage Cited in: EMBO J. 2019 Mar 15;38(6):e100376. [Abstract]
- Brcc3+/+ and Brcc3-/- (Abro1+/+ and Abro1-/-)BMDMs are treated with or without LPS for 1 h. Before LPS treatment, Brcc3-/- (Abro1-/-) BMDMs are pretreated with MG132 (10 μM) for 6 h to rescue the expression of ABRO1. Immunoblot analysis of NLRP3 and ABRO1 proteins in cell lysates immunoprecipitated with anti-ABRO1 antibody.
-
MG-132 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 Feb 26;38(1):101. [Abstract]
- HLF and Hep3B cells are treated with Mg132 (10 μg/ml) for 4 h, total protein is extracted and subjected to western blotting using anti-Flag, anti-p21, or anti-GAPDH antibodies.
-
MG-132 purchased from MedChemExpress. Usage Cited in: J Exp Bot. 2019 Sep 24;70(18):4749-4762. [Abstract]
- Cell-free degradation assay of recombinant His-PhCHS protein. Recombinant His- PhCHS is purified from Escherichia coli incubated with petal crude proteins at stages and treated with specific 26S proteasome inhibitor MG132 at various time intervals. Western blot analysis was conducted using an anti-His antibody and anti-β-actin protein concentration was used as a loading control.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Antioxid Redox Signal. 2019 May 20;30(15):1831-1848. [Abstract]
- Tan-IIA increases the endogenous induction of Nrf2 induction and this effect is further enhanced by cotreatment with the proteasome inhibitor MG-132.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Molecules. 2019 Jan 22;24(3):393. [Abstract]
- The HepG2 cells are pretreated for 5 h MG 132 which is a proteasome inhibitor. Then, the MARCH1 protein expressions in HepG2 cells treated with 0 μM, 5,0 μM SAF, and 2.5 μM MG 132 are measured by immunoblotting.
-
MG-132 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 3;37(1):240. [Abstract]
- Decrease of ERCC6 expression can be rescued with proteasome inhibitor MG132. Subconfluent SKOV3 cells are treated with FL118 and MG132 alone or in combination as shown for 8 h, followed by western blot analyses with ERCC6 antibody.
-
MG-132 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Aug 15;37(1):193. [Abstract]
- Western blot is performed in HCC-LM3 cells transfected with HJURP knockdown lentivirus and treated with DMSO or MG132.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2019 Feb 1;79(3):534-545. [Abstract]
- Cells are transfected with GYS2 siRNA and pre-incubated with MG-132 (20 μM) for 12 h. Cell lysate are immunoprecipitated by anti-Ub and immunoblotted by anti-p53.
-
MG-132 purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2018 Aug;34:243-255. [Abstract]
- MPC1 protein expression in primary mouse hepatocytes incubated with pyruvate for 8 h in the presence of MG-132.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 May 22;9(6):604. [Abstract]
- Different concentrations of two classical proteasome inhibitors PS-341 and MG132 are added. AGS cells are either untreated or treated with PS-341 (25 nM) or MG132 (0.1 μM) for 24 h in the absence or presence of baf A1 (100 nM).
-
MG-132 purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2018 Aug;51(4):e12451. [Abstract]
- Immunoblot analysis of CDK4 in cells treated with 4 μM of CGN for 24 hours in the presence and absence of MG132.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2018 Feb 1;146:251-259. [Abstract]
- In the absence of MG132, the protein degradation pathways are intact, the Tau protein level is significantly decreased in peptide 1-treated group.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 Oct;156:511-523. [Abstract]
- The accumulated poly-ubiquitinated protein is detected by Western blotting after J-Lat 10.6 cells are treated with DMSO, PR-957 (100 nM), PR-957 (150 nM) or MG132 (500 nM) for 48 h.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Apr 19;9:377. [Abstract]
- Immunoblot levels of highly molecular weight (HMW)-ubiquitinated proteins and pSer129-α-syn after inhibiting the ubiquitin-proteasome system (UPS) by various concentrations of MG132 (0.25, 0.5, and 1 μM) in SH-SY5Y cells.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Mol Plant Pathol. 2018 Dec;19(12):2623-2634. [Abstract]
- Destabilization of BRC1 mediated by SWP1 is inhibited by proteasome inhibitors Epoxomicin and MG132.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Cell Cycle. 2018;17(13):1591-1601. [Abstract]
- The protein level of CCNB1 in different groups is analyzed by Western blot; MG132 significantly increases the protein level of CCNB1 in oocytes from CRS group mice. Western blotting showing the reduced expression of securin is rescued by MG132 in CRS group mouse oocytes.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Mol Immunol. 2018 Nov 13;104:69-78. [Abstract]
- Western analysis of proteins expression with treatment of IKK-16 or MG-132.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Nov;16(5):5900-5906. [Abstract]
- Treatment with the 26S proteasome inhibitor, MG 132 (10 µM), rescues the downregulation of NEK 8 in the pVHL overexpressing SGC 7901 cells.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3322-3338. [Abstract]
- The neonatal rat cardiomyocytes (NRCMs) are treated with MG132 (10 μM). The protein expression level of PPARα in the indicated group.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 Dec 1;410:112-123. [Abstract]
- Immunoprecipitation of ubiquitin from lysates of U-2 OS cells expressing CHOP after treatment with different concentrations of MG7 for 48 h. Cells are incubated with MG132 (20 mM) for 4 h before harvest. Cell lysates are immunoblotted with the indicated antibodies.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 Jun 7;7(1):2929. [Abstract]
- p53 and Cell apoptosis. MCF7 and MDA-MB-231 cells are treated with 80 μM ω-3 FFAs, 20 μM ATRA alone or in combination for 48 h. The expression of PARP and p53 protein. β-Actin is used as an internal control.
-
MG-132 purchased from MedChemExpress. Usage Cited in: J Inorg Biochem. 2017 Oct;175:92-100. [Abstract]
- TPEN-triggered PML-RARα degradation in NB4 cells is reversed by MG-132 treatment. NB4 cells are treated with 5 μM TPEN with or without the presence of 1 μM MG-132 for the indicated durations (0–12 h) and then lysed. The lysates are analyzed for PML-RARα and RARα protein levels by western blotting.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2017 Sep 2;490(4):1168-1175. [Abstract]
- Treatment of CHO-K1 cells with proteasome inhibitor, MG-132 results in elevated SR-B1 protein levels. The cells with MG-132, a potent proteasome inhibitor that inhibit ubiquitin/proteasome-dependent protein degradation, and MG-132 treatment significantly enhances cellular SR-B1 protein level.
-
MG-132 purchased from MedChemExpress. Usage Cited in: Université de Montréal. Octobre 2017.
- Unsynchronized control and ARF6 cells are treated with DMSO or MG132 (10 μM) for 1h or 4h, lysed and total ubiquitinated proteins are determined using western blot (n=3).
Biological Activity
Purity & Documentation
References
Customer Review
Description |
MG-132 (Z-Leu-Leu-Leu-al) is a potent proteasome and calpain inhibitor with IC50s of 100 nM and 1.2 μM, respectively. MG-132 effectively blocks the proteolytic activity of the 26S proteasome complex. MG-132, a peptide aldehyde, also is an autophagy activator. MG-132 also induces apoptosis[1][2][3]. |
IC50 & Target | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In Vitro |
MG-132 (Z-Leu-Leu-Leu-al) initiates neurite outgrowth in PC12 cells at a low concentration (30 nM) and is a very strong inhibitor of 20S proteasome[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay[3]
Western Blot Analysis[3]
|
||||||||||||||||
In Vivo |
MG132 (10 mg/kg; i.p.; daily for 25 days starting 5 days after EC9706 cells injection) significantly inhibits tumor growth of the EC9706 xenograft without causing toxicity to mice[7]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
Molecular Weight |
475.62 |
||||||||||||||||
Formula |
C26H41N3O5 |
||||||||||||||||
CAS No. | |||||||||||||||||
Appearance |
Solid |
||||||||||||||||
Color |
White to yellow |
||||||||||||||||
SMILES |
O=C(OCC1=CC=CC=C1)N[C@H](C(N[C@@H](CC(C)C)C(N[C@H](C(00)=O)CC(C)C)=O)=O)CC(C)C |
||||||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
Storage |
|
||||||||||||||||
Solvent & Solubility |
In Vitro:
DMSO : 100 mg/mL (210.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||||||
Purity & Documentation | |||||||||||||||||
References |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 2.1025 mL | 10.5126 mL | 21.0252 mL | 52.5630 mL |
5 mM | 0.4205 mL | 2.1025 mL | 4.2050 mL | 10.5126 mL | |
10 mM | 0.2103 mL | 1.0513 mL | 2.1025 mL | 5.2563 mL | |
15 mM | 0.1402 mL | 0.7008 mL | 1.4017 mL | 3.5042 mL | |
20 mM | 0.1051 mL | 0.5256 mL | 1.0513 mL | 2.6281 mL | |
25 mM | 0.0841 mL | 0.4205 mL | 0.8410 mL | 2.1025 mL | |
30 mM | 0.0701 mL | 0.3504 mL | 0.7008 mL | 1.7521 mL | |
40 mM | 0.0526 mL | 0.2628 mL | 0.5256 mL | 1.3141 mL | |
50 mM | 0.0421 mL | 0.2103 mL | 0.4205 mL | 1.0513 mL | |
60 mM | 0.0350 mL | 0.1752 mL | 0.3504 mL | 0.8760 mL | |
80 mM | 0.0263 mL | 0.1314 mL | 0.2628 mL | 0.6570 mL | |
100 mM | 0.0210 mL | 0.1051 mL | 0.2103 mL | 0.5256 mL |
MG-132 Related Classifications
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Keywords:
MG-132133407-82-6Z-Leu-Leu-Leu-al MG132MG132MG 132ProteasomeAutophagyApoptosispeptidealdehydeproteolytic26SproteasomecomplexcalpainInhibitorinhibitorinhibit
Your Recently Viewed Products:
Inquiry Online
Your information is safe with us. * Required Fields.
Bulk Inquiry
Inquiry Information
- Product Name:
- MG-132
- Cat. No.:
- HY-13259
- Quantity:
- MCE Japan Authorized Agent: